Lakis Sotiris, Kotoula Vassiliki, Eleftheraki Anastasia G, Batistatou Anna, Bobos Mattheos, Koletsa Triantafyllia, Timotheadou Eleni, Chrisafi Sofia, Pentheroudakis George, Koutras Angelos, Zagouri Flora, Linardou Helena, Fountzilas George
Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
Breast. 2014 Jun;23(3):234-43. doi: 10.1016/j.breast.2014.02.013. Epub 2014 Apr 3.
The Androgen Receptor (AR) is a potential prognostic marker and therapeutic target in breast cancer. We evaluated AR protein expression in high-risk breast cancer treated in the adjuvant setting. Tumors were subtyped into luminal (ER+/PgR±/AR±), molecular apocrine (MAC, [ER-/PgR-/AR+]) and hormone receptor negative carcinomas (HR-negative, [ER-/PgR-/AR-]). Subtyping was evaluated with respect to prognosis and to taxane therapy. High histologic grade (p < 0.001) and increased proliferation (p = 0.001) more often appeared in MAC and HR-negative than in luminal tumors. Patients with MAC had outcome comparable to the luminal group, while patients with HR-negative disease had increased risk for relapse and death. MAC outcome was favorable upon taxane-containing treatment; this remained significant upon multivariate analysis for overall survival (HR 0.31, 95%CI 0.13-0.74, interaction p = 0.035) and as a trend for time to relapse (p = 0.15). In conclusion, AR-related subtyping of breast cancer may be prognostic and serve for selecting optimal treatment combinations.
雄激素受体(AR)是乳腺癌潜在的预后标志物和治疗靶点。我们评估了辅助治疗的高危乳腺癌中AR蛋白的表达情况。肿瘤被分为腔面型(ER+/PgR±/AR±)、分子大汗腺型(MAC,[ER-/PgR-/AR+])和激素受体阴性癌(HR阴性,[ER-/PgR-/AR-])。对各亚型的预后和紫杉烷治疗情况进行了评估。与腔面型肿瘤相比,高组织学分级(p < 0.001)和增殖增加(p = 0.001)在MAC和HR阴性肿瘤中更常见。MAC患者的预后与腔面型组相当,而HR阴性疾病患者的复发和死亡风险增加。含紫杉烷治疗对MAC患者的预后有利;在多因素分析总体生存情况时,这一结果仍具有显著性(HR 0.31,95%CI 0.13 - 0.74,交互作用p = 0.035),且在复发时间方面呈趋势性显著(p = 0.15)。总之,基于AR的乳腺癌亚型分类可能具有预后价值,并有助于选择最佳治疗方案。